RSS

Lenvatinib

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Interim results from the advanced renal cell carcinoma (RCC) cohort of a study evaluating Kisplyx (lenvatinib) in combination with Merck’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA), have been announced by Eisai. more

News

Global research and development-based pharmaceutical company, Eisai, has submitted a marketing authorization application to the European Medicines Agency (EMA) for its first-line hepatocellular carcinoma treatment, lenvatinib. more

News

Lenvatinib, discovered and developed by Eisai, has been submitted for review by the European Medicines Agency (EMA) for use in combination with everolimus to treat people with metastatic kidney cancer more

News